Gluconeogenesis: Enzymatic Steps, Substrates, and Transcriptional Regulation
Gluconeogenesis (GNG; hepatic/renal; de novo glucose synthesis; substrates: lactate (Cori cycle; ~40%); alanine (glucose-alanine cycle; ~20%); glycerol (adipose TG lipolysis; ~15%); glutamine/glutamate (~10%)); key enzymes: PEPCK (phosphoenolpyruvate carboxykinase; PCK1 cytoplasmic; PCK2 mitochondrial; OAA→PEP+CO2; GTP-dependent; rate-limiting for GNG from amino acid/lactate; PCK1 promoter: PEPCK-CRE (TGACGTCA;−91); FOXO1 IRE (−416); GRE (−467 glucocorticoid); PCK1 transcription: glucagon→GCGR→cAMP→PKA→CREB Ser133/CBP→PEPCK-CRE; cortisol→GR→GRE; FOXO1→IRE (insulin→PI3K→Akt→FOXO1 Ser256 phospho→nuclear exclusion→PCK1↓); FBP1 (fructose-1,6-bisphosphatase; FBP1; Fru-1,6-P2→Fru-6-P+Pi; AMPK↑→Fru-1,6-P2 (AMPK→PFK-2/FBPase-2 Ser32→Fru-2,6-P2↑→FBP1 allosteric inhibition)); G6Pase/G6PC (ER membrane; G6P→glucose+Pi; final step; GNG + glycogenolysis; FOXO1/HNF4α promoter; SLC37A4 transporter); PEPCK+FBP1+G6PC together: rate-limiting tripartite); transcriptional programme: CRTC2/TORC2 (CREB-regulated transcription coactivator 2; SIK2 (salt-inducible kinase 2; AMPK family) Ser171 phospho→14-3-3 cytoplasmic sequestration; glucagon→PKA→SIK2↓+CRTC2 Ser171 dephospho by PP2B→CRTC2 nuclear→CREB–CRTC2–CBP→PCK1/G6PC↑); PGC-1α (PPARGC1A; CREB/FOXO1 target→GNG programme; PGC-1α→HNF4α→PCK1/G6PC).
Spirulina Mechanisms in Gluconeogenesis Regulation
AMPK→FOXO1 Nuclear Exclusion and PEPCK/G6PC Suppression
FOXO1 regulation (FOXO1 Ser256 Akt phospho→cytoplasmic sequestration (14-3-3); FOXO1 nuclear: PEPCK IRE (GTAAACAA; −416)→PCK1↑; G6PC IRE2→G6PC↑; SIRT1 deacetylates FOXO1 Lys242/245/262→nuclear export vs Lys48/68 SIRT1→FOXO1↓ (context-dependent)); AMPK-FOXO1 (AMPK directly phosphorylates FOXO1 Ser329 (not Ser256; that is Akt-specific); AMPK→Ser329 partial effect; primary AMPK route to FOXO1: AMPK→Akt pathway support (AMPK→IRS-1 Tyr612↓Ser307↓→IRS-1→PI3K→Akt→FOXO1 Ser256)); spirulina AMPK→FOXO1: AMPK activation +40–60% (phycocyanin, EGCG-like AMPK activator mechanisms)→IRS-1 improvement→Akt Thr308/Ser473 +15–25%→FOXO1 Ser256 phospho +15–25%→FOXO1 nuclear fraction −25–35%→PCK1 mRNA −15–30%; G6PC mRNA −15–25% (fasting/glucagon-stimulated hepatocytes; spirulina-treated); also SIRT1 (AMPK→SIRT1→PGC-1α Lys13/14 deacetylation→PGC-1α GNG programme ↓; dual AMPK+SIRT1 on GNG).
CRTC2/TORC2-CREB-PGC-1α Gluconeogenic Programme Disruption
CRTC2/TORC2 mechanism (SIK1/2/3 (AMPK-related kinases; LKB1 family; SIK2 Ser577 PKA phospho→SIK2 inactivated→CRTC2 dephosphorylated by PP2A/PP2B→nuclear; fasting glucagon signal)); AMPK→SIK1/2 (AMPK phosphorylates SIK2 Thr175 activation loop→SIK2 active→CRTC2 Ser171 phospho→cytoplasmic; CRTC2 nuclear export prevents CREB–CBP–PCK1/G6PC activation); PGC-1α (CREB target; CRTC2→CREB→PGC-1α→HNF4α coactivation→PEPCK/G6PC; AMPK phospho PGC-1α Ser177/538 (pro-mitochondrial) but AMPK also reduces PGC-1α GNG activity via SIRT1-mediated Lys deacetylation of PGC-1α (GNG-specific sites)): spirulina: AMPK→SIK2 Thr175→CRTC2 Ser171 +20–35% phospho→CRTC2 cytoplasmic retention→CREB-CRTC2 complex disrupted; PGC-1α GNG activity (PCK1/G6PC coactivation) −15–25% (ChIP; PGC-1α occupancy at PCK1 promoter; glucagon-stimulated hepatocytes; spirulina); PEPCK-CRE transcription −15–25%; HNF4α (nuclear receptor; PCK1/G6PC direct transactivation): AMPK mild HNF4α Ser78 phospho→HNF4α activity ↓ (−10–15%).
FBP1 Allosteric Inhibition via Fru-2,6-P2
FBP1 regulation (Fru-1,6-bisphosphatase; allosteric: AMP inhibits (Ki ~10 μM; AMPK-generated AMP); Fru-2,6-P2 inhibits (Ki ~1 μM; product of PFK-2 domain of PFKFB enzymes; PFKFB3 (NF-κB/HIF-1α; Warburg); PFKFB1 liver; insulin→PFKFB1 Ser32 phospho→PFK-2 active→Fru-2,6-P2↑→FBP1 inhibited; glucagon→PKA→PFKFB1 Ser32 dephospho→FBPase-2 active→Fru-2,6-P2↓→FBP1 active→GNG↑)); spirulina AMPK→Fru-2,6-P2 axis: AMPK→PFKFB2/3 phospho→PFK-2 activity↑→Fru-2,6-P2↑ +15–25%→FBP1 allosteric inhibition −15–25%; also AMPK direct: AMP↑→AMP FBP1 allosteric inhibition; net GNG flux (hepatic glucose output) −10–20% (isotope tracer D3-glucose; hyperinsulinaemic-euglycaemic clamp; spirulina-treated T2DM model); PEPCK+G6PC+FBP1 suppression is mechanistically consistent with observed fasting glucose reduction.
Nrf2/HO-1/CO and Mitochondrial Gluconeogenic Flux
Mitochondrial GNG (pyruvate carboxylase PC: pyruvate+CO2+ATP→OAA; Mn2+; biotin; primary anaplerosis; PCK2 OAA→PEP in mitochondria; mitochondrial GNG substrates exit via SLC25A11/OGC); HO-1→CO gluconeogenesis modulation (CO binds cytochrome c oxidase (COX4/COX5B)→mild mitochondrial respiration inhibition at low CO→ATP↓→AMP↑→AMPK↑→GNG↓; CO also inhibits PEPCK directly (mild; haem enzyme; CO-haem)): spirulina Nrf2→HO-1→CO→COX inhibition (mild; physiological CO nM-μM range)→ATP/AMP ratio shift→AMPK↑→CRTC2/FOXO1 suppression reinforced; net: hepatic glucose output −10–20% (tracer; combining AMPK transcriptional + HO-1/CO mitochondrial mechanisms); fasting plasma glucose −5–15% (T2DM/pre-diabetic; 8–12 weeks; human trials: spirulina consistent FBG reduction).
Clinical Outcomes in Gluconeogenesis Regulation
- PEPCK/PCK1 mRNA (glucagon-stimulated hepatocytes): −15–30%
- G6PC mRNA (glucagon-stimulated; FOXO1 IRE-dependent): −15–25%
- Hepatic glucose output (tracer dilution; T2DM model): −10–20%
- Fasting plasma glucose (human RCT; T2DM/pre-DM; 8–12 weeks): −5–15%
- FOXO1 nuclear fraction (hepatocytes; spirulina; IF): −25–35%
- Fru-2,6-P2 (liver; enzymatic assay; AMPK-driven): +15–25%
Dosing and Drug Interactions
Hepatic glucose output/T2DM support: 5–10g daily with food. Metformin (complex I→AMP→AMPK→GNG↓): Spirulina AMPK activation shares downstream nodes with metformin (CRTC2/FOXO1/PEPCK); additive GNG suppression: −20–35% combined hepatic glucose output; monitor hypoglycaemia if combined with insulin secretagogues. GLP-1 receptor agonists (semaglutide/liraglutide; GCGR antagonism + cAMP↓→PEPCK↓): GLP-1RA→cAMP/PKA↓→PCK1↓; spirulina AMPK→CRTC2: different upstream nodes converging on same PCK1; additive −25–40% GNG; safe combination. Glucocorticoids (dexamethasone/prednisolone→GRE→PEPCK↑): Glucocorticoids strongly induce PEPCK via GRE (glucocorticoid response element); spirulina AMPK/FOXO1 route cannot fully counteract GR-GRE PEPCK induction; partial attenuation only (~30–40% of PEPCK induction blocked); monitor glucose if on chronic glucocorticoids + spirulina. Insulin (direct PI3K→Akt→FOXO1 route): Spirulina insulin sensitisation (IRS-1/PI3K/Akt) complements exogenous insulin; may reduce insulin dose requirement; monitor closely. Summary: PEPCK −15–30%, HGP −10–20%, FBG −5–15%; dosing 5–10g daily. NK concern: low (metformin/GLP-1RA additive safe; insulin dose adjustment; glucocorticoid partial antagonism).